The Congressional Budget Office has said that the Senate version of the Republicans’ Affordable Care Act replacement bill could result in 22 million fewer Americans with health insurance.
That dramatic reduction in coverage could have major implications for drug makers offering expensive treatments for HIV, Citi analyst Andrew Baum wrote on Wednesday.
The current HIV treatment market is roughly a $16 billion business. However, the top competitors in the HIV market may see their customer base shrink significantly if the ACA is repealed.
“Potential repeal of ACA in the absence of offsetting federal funding would represent an additional $2.3bn downgrade to our current HIV market forecast by 2025 due to a funding gap from newly uninsured and under-insured patients previously covered through Medicaid expansion coupled with pressure on net drug pricing through restricted formularies,” Baum wrote.
Repeal could be bad news for GlaxoSmithKline plc (ADR) GSK 0.26%, whose ViiV Healthcare joint venture with Pfizer Inc. PFE 0.18% could take a hit. Earlier this month, ViiV submitted a simpler, two-drug HIV treatment regiment for regulatory approval. However, with fewer Americans insured, previous assumptions about how much revenue these drugs could generate may need to be revised lower.
Citi has cut its ViiV revenue forecast by 13 percent and downgraded GlaxoSmithKline’s stock from Buy to Neutral.
While ACA repeal could hit certain drug stocks hard, the biggest fallout may have nothing to do with the stock market.
“From a public health perspective, we are…
Click here to continue reading
Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!
